Format

Send to:

Choose Destination
See comment in PubMed Commons below
Clin Nutr. 2014 Feb;33(1):156-63. doi: 10.1016/j.clnu.2013.03.013. Epub 2013 Mar 26.

Wogonin ameliorates hyperglycemia and dyslipidemia via PPARα activation in db/db mice.

Author information

  • 1Oral Cancer Research Institute, Yonsei University College of Dentistry, Seoul, Republic of Korea.
  • 2Research Center for Orofacial Hard Tissue Regeneration, College of Dentistry, Yonsei University, Seoul, Republic of Korea; Department of Applied Life Science, Yonsei University Graduate School, Seoul, Republic of Korea; Department of Oral Biology, Yonsei University College of Dentistry, Seoul, Republic of Korea.
  • 3Department of Applied Life Science, Yonsei University Graduate School, Seoul, Republic of Korea; Department of Oral Biology, Yonsei University College of Dentistry, Seoul, Republic of Korea.
  • 4Department of Clinical Science, Semyung University, Jecheon, Republic of Korea.
  • 5Oral Cancer Research Institute, Yonsei University College of Dentistry, Seoul, Republic of Korea; Research Center for Orofacial Hard Tissue Regeneration, College of Dentistry, Yonsei University, Seoul, Republic of Korea; Department of Applied Life Science, Yonsei University Graduate School, Seoul, Republic of Korea; Department of Oral Biology, Yonsei University College of Dentistry, Seoul, Republic of Korea.
  • 6Research Center for Orofacial Hard Tissue Regeneration, College of Dentistry, Yonsei University, Seoul, Republic of Korea; Department of Applied Life Science, Yonsei University Graduate School, Seoul, Republic of Korea; Department of Oral Biology, Yonsei University College of Dentistry, Seoul, Republic of Korea. Electronic address: yu618@yuhs.ac.

Abstract

BACKGROUND & AIMS:

Wogonin is a flavonoid extracted from the root of Scutellaria baicalensis Gerogi. We evaluated the therapeutic effects of wogonin using db/db mice.

METHODS:

Mice received wogonin or vehicle by oral gavage for 2 weeks. Blood glucose, insulin, and cholesterol levels were measured, and liver morphology was observed with histopathological analysis. The mRNA expression levels of PPARα, PPARγ, and adiponectin in the liver and white adipose tissue (WAT) were determined by real-time PCR. Immunoblotting for AMPK and PPARγ, and adipocyte differentiation were investigated in vitro using 3T3-L1 cells. A luciferase assay was used to measure PPARα and PPARγ binding activity.

RESULTS:

The wogonin group showed decreased weight gain without a change in food intake and improved glucose tolerance. Serum insulin and cholesterol levels in the wogonin group were significantly decreased compared to those in the control group. The wogonin group also showed less accumulation of lipid droplets and glycogen in the liver. PPARα and PPARγ expression levels in the liver and WAT and adiponectin expression level in WAT in the wogonin group were higher than those in the control group. In 3T3-L1 cells, wogonin was shown to stimulate AMPK activation in a dose-dependent manner. The presence of wogonin did not affect adipocyte differentiation or PPARγ protein level during adipogenesis. Notably, wogonin enhanced PPARα but not PPARγ transactivation.

CONCLUSIONS:

These indicate that wogonin may have beneficial effects on glucose and lipid metabolism related to enhanced PPARα and adiponectin expression via AMPK activation. Importantly, wogonin did not cause deleterious effects, such as weight gain and fatty liver. Wogonin might be a useful therapeutic agent to treat type 2 diabetes.

Copyright © 2013 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.

KEYWORDS:

Hyperglycemia; Hyperlipidemia; Insulin; PPAR; Type 2 diabetes; Wogonin

PMID:
23623334
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk